electroCore to Participate at H.C. Wainwright Global Investment Conference
electroCore (NASDAQ:ECOR), a bioelectronic medicine and wellness company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will be held on September 9, 2025, at the Lotte New York Palace Hotel in New York.
The company's management team will be available for one-on-one meetings throughout the conference day. Interested investors can schedule meetings through their H.C. Wainwright sales representative or by contacting electroCore's Investor Relations directly.
electroCore (NASDAQ:ECOR), azienda nel settore della medicina bioelettronica e del benessere, ha annunciato la sua partecipazione al H.C. Wainwright 27th Annual Global Investment Conference. L'evento si terrà il 9 settembre 2025 presso il Lotte New York Palace Hotel di New York.
Il team dirigenziale della società sarà disponibile per incontri one-to-one durante la giornata della conferenza. Gli investitori interessati possono programmare gli incontri tramite il loro rappresentante di vendita H.C. Wainwright o contattando direttamente l'Investor Relations di electroCore.
electroCore (NASDAQ:ECOR), una compañía de medicina bioelectrónica y bienestar, anunció su participación en la H.C. Wainwright 27th Annual Global Investment Conference. El evento se celebrará el 9 de septiembre de 2025 en el Lotte New York Palace Hotel de Nueva York.
El equipo directivo de la compañía estará disponible para reuniones individuales durante la jornada de la conferencia. Los inversores interesados pueden programar reuniones a través de su representante de ventas de H.C. Wainwright o contactando directamente con el Investor Relations de electroCore.
electroCore (NASDAQ:ECOR)는 바이오일렉트로닉 의학 및 웰니스 기업으로, H.C. Wainwright 27th Annual Global Investment Conference에 참여한다고 발표했습니다. 해당 행사는 2025년 9월 9일 뉴욕의 롯데 뉴욕 팰리스 호텔에서 개최됩니다.
회사 경영진은 컨퍼런스 당일 일대일 미팅을 진행할 예정입니다. 미팅을 원하시는 투자자는 H.C. Wainwright 영업 담당자 또는 electroCore의 투자자 관계팀에 직접 연락하여 일정을 잡을 수 있습니다.
electroCore (NASDAQ:ECOR), entreprise de médecine bioélectronique et de bien‑être, a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference. L'événement aura lieu le 9 septembre 2025 à l'hôtel Lotte New York Palace à New York.
L'équipe de direction de la société sera disponible pour des rencontres individuelles pendant la journée de la conférence. Les investisseurs intéressés peuvent planifier des réunions via leur représentant commercial H.C. Wainwright ou en contactant directement le service des relations investisseurs d'electroCore.
electroCore (NASDAQ:ECOR), ein Unternehmen für bioelektronische Medizin und Wellness, hat seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference angekündigt. Die Veranstaltung findet am 9. September 2025 im Lotte New York Palace Hotel in New York statt.
Das Managementteam des Unternehmens steht während des Konferenztages für Eins-zu-eins-Gespräche zur Verfügung. Interessierte Investoren können Termine über ihren H.C. Wainwright-Vertriebsmitarbeiter oder durch direkte Kontaktaufnahme mit der Investor-Relations-Abteilung von electroCore vereinbaren.
- None.
- None.
ROCKAWAY, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference. The conference will take place in New York on Tuesday, September 9, 2025 at the Lotte New York Palace Hotel. Management will host one-on-one meetings throughout the day.
Investors who wish to request a meeting should contact their sales representative at H.C. Wainwright or reach out to electroCore Investor Relations at ecor@fnkir.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
When is electroCore (ECOR) presenting at the H.C. Wainwright Conference?
How can investors schedule meetings with electroCore management at the H.C. Wainwright Conference?
Where will the H.C. Wainwright Global Investment Conference with electroCore take place?
What type of meetings will electroCore management host at the H.C. Wainwright Conference?
